Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases

Last updated: July 9, 2020
Sponsor: AUM Cardiovascular, Inc.
Overall Status: Completed

Phase

N/A

Condition

Chest Pain

Cardiovascular Disease

Myocardial Ischemia

Treatment

N/A

Clinical Study ID

NCT01743040
1038-001
  • Ages > 22
  • All Genders

Study Summary

This is a multi-center, prospective, non-randomized, double-blinded trial to evaluate the sensitivity and specificity of the CADence device in detecting the existence of clinically significant coronary artery disease as determined by either standard or CT angiography.

Eligibility Criteria

Inclusion

Subjects clinically indicated for nuclear stress test and who satisfy all the inclusion andexclusion criteria are eligible for participation. Inclusion criteria: Age 22 years or older Willing and able to give informed consent Clinical indication fornuclear stress test evaluation Chest pain syndrome Two or more coronary artery disease risk factors as defined by:

  1. Dyslipidemia: low-density lipoprotein (LDL) >130 mm/dL or high-density lipoprotein (HDL) <35 mm/dL or on treatment for dyslipidemia

  2. Hypertension: blood pressure >140 millimeter of mercury (mmHg) systolic, >90 mmHgdiastolic or on blood pressure altering treatment

  3. Obesity: body mass index (BMI)>28

  4. Current cigarette smoking

  5. Diabetes: Type 1 or 2

  6. Family history: coronary disease in a first or second degree relative

Exclusion

Exclusion criteria: Body Mass Index (BMI)<18.5 or BMI >40 Known coronary disease as defined as: Prior bypass surgery or coronary stenting Q-wave infarction on a past electrocardiogram (EKG) (>0.01 sec Q-wave duration in two adjacent leads) Presence of pacemaker/defibrillator Presence of artificial valve Presence of obviouscyanotic or pre-diagnosed congenital heart defect and coarctation of the aorta Presencemurmurs including valve lesions, ventricular septal defects, and arteriovenous (AV)fistulae. Presence of moderate or severe valve disease as defined by >1/6 heart murmur on physicaldiagnosis Left Ventricular Assist Device (LVAD) Presence of scars on the site thorax areasParticipation in trial within 30 days prior to collecting CADence data except participationin registry studies Asthma with wheezing Inability to lie flat in the supine position Acutecoronary syndrome with elevated cardiac biomarkers (troponin (TP)>3x upper limit of normal (ULN) or creatine kinase MB (CKMB) >3x ULN) Heart Transplant Current cocaine use (withinthe past 24 hours, as reported by subject) Chronic Obstructive Pulmonary Disease (COPD)Contraindication to computed tomography (CT) angiography

  • Renal failure with glomerular filtration rate (GFR)<50 (angio risk)

  • Iodinated contrast allergy

  • Elevated heart rate which cannot be controlled sufficiently to achieve a good computedtomography angiogram

  • Body weight >350lbs.

  • Sinus rhythm rate greater than 100 beats per minute at screening.

  • Atrial fibrillation with average heart rate of greater than 70 beats per minute onresting screening electrocardiogram (ECG).

Study Design

Total Participants: 1014
Study Start date:
June 14, 2013
Estimated Completion Date:
February 10, 2016

Study Description

This is a multi-center, prospective, non-randomized, double-blinded, trial to evaluate the performance of the CADence in detecting the existence of at least one major coronary artery with clinically significant stenosis in a subject is defined as the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex, mid Left Circumflex , proximal Right Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment diameter >2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries.

Consented subjects will be evaluated with the CADence device and then undergo nuclear stress testing followed by either computed tomography or standard coronary angiography. The maximum expected timeframe between CADence and computed tomography Angiography or standard angiography is 6 weeks.

This is a double-blinded study. All physicians and subjects will be masked to the diagnostic results of the CADence until completion of CADence, nuclear stress, computed tomography or standard coronary angiogram testing for the subjects. Patient care will not be based on the CADence results.

Study participation will conclude after the computed tomography angiography or standard coronary angiography procedure.

computed tomograph or standard coronary angiography are considered acceptable clinical reference standards in this study and are gold standards for detection of coronary artery disease. The experimental unit of this study is the subject. Existence of clinically significant coronary artery disease in a subject is defined as the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment diameter >2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries.

The study required sample size is 826 but may enroll up to 1,300 subjects. The sensitivity and specificity of the CADence are expected to be 80% and 73% respectively. Observed sensitivity and specificity will be compared to nuclear stress literature-based performance standards of 83% and 80% respectively using one sample non-inferiority binomial tests with a non-inferiority margin of 15 percentage points. Sample size requirements are 109 subjects with the presence of at least one lesion with ≥ ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment diameter >2.5 mm or ≥50% diameter stenosis in the Left MAIN coronary arteries. to test the sensitivity hypothesis and 268 subjects without the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment diameter >2.5 mm or ≥50% diameter stenosis in the Left MAIN coronary arteries. to test the specificity hypothesis. It was assumed that 15 percent of enrolled subjects would be found to have the presence of at least one lesion with ≥ 70% diameter stenosis anywhere in the proximal Left anterior Descending, mid Left anterior Descending, proximal Left Circumflex, mid Left Circumflex, proximal Right Coronary Artery, mid Right Coronary Artery, distal Right Coronary Artery and Obtuse Margin 1, Obtuse Margin 2, and Ramus Intermedius if segment diameter >2.5 mm or ≥50% diameter stenosis in the Left Main coronary arteries. In order to accrue 109 subjects with significant Coronary Artery Disease as defined in the protocol, 826 subjects must be enrolled. Sample sizes provide 85% power with alpha of 0.05 for each statistical test.

Connect with a study center

  • University of Alabama

    Birmingham, Alabama 35294
    United States

    Site Not Available

  • Heart Center Research, LLC

    Huntsville, Alabama 35801
    United States

    Site Not Available

  • Cardiology Associates of Mobile

    Mobile, Alabama 36608
    United States

    Site Not Available

  • UCLA

    Los Angeles, California 90502
    United States

    Site Not Available

  • Hartford Hospital

    Hartford, Connecticut 06102
    United States

    Site Not Available

  • MedStar Washington Hospital Center

    Washington, District of Columbia 20010
    United States

    Site Not Available

  • Clearwater Cardiovascular

    Clearwater, Florida 33756
    United States

    Site Not Available

  • Iowa Heart Center

    Des Moines, Iowa 50314
    United States

    Site Not Available

  • MedStar Union Memorial Hospital

    Baltimore, Maryland 21218
    United States

    Site Not Available

  • Henry Ford Hospital

    Detroit, Michigan 48202
    United States

    Site Not Available

  • Mercy Hospital

    Coon Rapids, Minnesota 55433
    United States

    Site Not Available

  • Abbott/Minneapolis Heart Institute

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

  • University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

  • Mayo Clinic

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • CentraCare Heart & Vascular Center

    Saint Cloud, Minnesota 56303
    United States

    Site Not Available

  • HealthEast - St. Joseph's Hospital

    Saint Paul, Minnesota 55102
    United States

    Site Not Available

  • United Heart and Vascular Clinic

    Saint Paul, Minnesota 55102
    United States

    Site Not Available

  • CentraCare Heart & Vascular Center

    St. Cloud, Minnesota 56303
    United States

    Site Not Available

  • HealthEast - St. Joseph's Hospital

    St. Paul, Minnesota 55102
    United States

    Site Not Available

  • Mercy Hospital St. Louis

    Saint Louis, Missouri 63141
    United States

    Site Not Available

  • Mercy Hospital St. Louis

    St. Louis, Missouri 63141
    United States

    Site Not Available

  • Holy Name Medical Center

    Teaneck, New Jersey 07666
    United States

    Site Not Available

  • Columbia University

    New York, New York 10032
    United States

    Site Not Available

  • Mt. Sinai

    New York, New York 10032
    United States

    Site Not Available

  • Mt. Sinai

    New York City, New York
    United States

    Site Not Available

  • North Ohio Research

    Elyria, Ohio 44035
    United States

    Site Not Available

  • Lancaster General

    Lancaster, Pennsylvania 17602
    United States

    Site Not Available

  • Jackson Clinic

    Jackson, Tennessee 38301
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.